Shanghai Bio-heart Biological Technology Co., Ltd. dated December 29, 2021 and May 19, 2022 in relation to the RADIUS-HTN clinical trial. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Announcements. This announcement is made by the Company on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business advancement of the Group.

The Renal Artery Denervation Using Radial Access in Uncontrolled Hypertension (RADIUS-HTN) (the RADIUS-HTN Trial) is designed to evaluate the Company's Iberis® 2nd renal denervation (RDN) system in patients with uncontrolled hypertension. The RADIUS-HTN Trial will compare the effectiveness of renal denervation performed via transradial arterial access (TRA) and transfemoral arterial access (TFA). The principal investigator for the RADIUS-HTN Trial is Professor Felix Mahfoud, MD from Saarland University Hospital, Homburg/Saar and the chairman of the Arterial Hypertension Working Group of the German Cardiac Society.

The CERC is conducting the RADIUS-HTN Trial in Europe as contract research organization. The Board announced that on March 27, 2023, the first patient was enrolled in Bordeaux, France. The procedure was performed by a team led by Dr. Antoine Cremer at the Centre Hospitalier Universitaire de Bordeaux.

There were no reported complications or adverse events. The only company in the world to have CE Marking for catheters that can be used for both TRA and TFA to treat high blood pressure. The TRA approach to vascular interventions is preferred by physicians and patients.

Compared to TFA, TRA interventions reduce access site complications and shorten the duration of hospital stay with a reduction in procedural costs and increased patient gratification. Iberis® 2nd is a device-based, minimally invasive procedure for the treatment of high blood pressure. Clinical trials for Iberis ® 2nd are conducted in collaboration with Terumo, strategic business collaborator.

Information about RADIUS-HTN: On May 19, 2022, company announced that at EuroPCR 2022, which is an official annual meeting of the European Association of Percutaneous Cardiovascular Interventions, finalized plans with clinical trial investigators on the RADIUS-HTN Trial. The CERC will conduct the RADIUS-HTN Trial and evaluate the Company's Iberis ® 2nd transradial renal denervation (RDN) system in patients with uncontrolled hypertension.